Journal: BMC Biotechnology
Article Title: A TXNIP-driven bioluminescent reporter for high-throughput discovery of glycolytic inhibitors against renal cell carcinoma
doi: 10.1186/s12896-026-01111-7
Figure Lengend Snippet: 2-DG and its derivatives activate TXNIP promoter-driven luciferase expression in A498 cells. ( A – C ) Luciferase activity driven by the TXNIP promoter (A498-TXNIP-Pro-Luc2 cells) after 48 h treatment with 2-DG ( A ), 2-FG ( B ), and 2-DG-d ( C ). For 2-DG treatment, the concentration gradient was set as 0 mM (vehicle control, containing equal volume of DMSO), 5 mM, 10 mM, and 15 mM; while for 2-FG and 2-DG-d treatments, the concentration gradients were consistent: 0 mM (vehicle control), 1 mM, 2 mM, 5 mM, and 10 mM. ( D – F ) Luciferase activity in control A498-Luc2 cells after 48 h treatment with 2-DG ( D ), 2-FG ( E ), and 2-DG-d ( F ). The concentration gradients for each compound were the same as those described for A498-TXNIP-Pro-Luc2 cells above. ( G – I ) After treating A498-TXNIP-Pro-Luc2 cells with 2-DG ( G ), 2-FG ( H ), and 2-DG-d ( I ), for 48 h, flux measurements were acquired using the IVIS Lumina LT system. ( J – L ) After treating A498-Luc2 cells with 2-DG ( J ), 2-FG ( K ), and 2-DG-d ( L ) for 48 h, flux measurements were acquired using the IVIS Lumina LT system. Top, cellular images; bottom, normalized fold induction of TXNIP-Pro-Luc2 or Luc2 treated with the indicated doses of drugs. Quantified flux data were averaged ( n = 3) and plotted. The dosage of each compound was consistent with that used in the previous luciferase activity assay. Data are mean ± SEM ( n = 3); Statistical significance was analyzed by one-way ANOVA with Dunnett’s multiple comparisons; **** p < 0.0001, ** p < 0.01, * p < 0.05
Article Snippet: The human renal clear cell carcinoma cell line A498 (Cat. No. CL-0254, RRID: CVCL_1056) was purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China).
Techniques: Luciferase, Expressing, Activity Assay, Concentration Assay, Control